ORIC Pharmaceuticals Inc.

4.77
0.08 (1.71%)
At close: Apr 17, 2025, 3:59 PM
4.89
2.58%
After-hours: Apr 17, 2025, 07:50 PM EDT
1.71%
Bid 4.5
Market Cap 338.8M
Revenue (ttm) n/a
Net Income (ttm) -127.85M
EPS (ttm) -1.83
PE Ratio (ttm) -2.61
Forward PE -2.44
Analyst Buy
Ask 5.29
Volume 531,982
Avg. Volume (20D) 1,068,090
Open 4.76
Previous Close 4.69
Day's Range 4.59 - 4.78
52-Week Range 3.90 - 14.67
Beta 1.37

About ORIC

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; an...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 24, 2020
Employees 115
Stock Exchange NASDAQ
Ticker Symbol ORIC
Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for ORIC stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 319.29% from the latest price.

Stock Forecasts
1 month ago
+2.72%
Oric Pharmaceuticals shares are trading higher. JP... Unlock content with Pro Subscription
5 months ago
-0.42%
Oric Pharmaceuticals shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a price target of $17.